AUM Biosciences announces closing of $27 million in a "Series A" Round of funding to advance its clinical stage pipeline of precision and targeted cancer therapies

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/3Dvw8me
via IFTTT